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Osteonecrosis of the jaw (ONJ) is a site specific osseous pathology, characterized by chronic exposed bone in the mouth, which
needs to be reinforced periodically within the medical literature. ONJ is a clinical entity with many possible aetiologies and its
pathogenesis is not well understood. The risk factors for ONJ include bisphosphonates treatments, head and neck radiotherapy,
dental procedures involving bone surgery, and trauma. Management of ONJ has centred on efforts to eliminate or reduce severity
of symptoms, to slow or prevent the progression of disease, and to eradicate diseased bone. This case describes a rare case of ONJ
in a 64-year-old Caucasian male diagnosed with multiple myeloma stage III. The lesion was related to a traumatic injury during
mastication. Eighteen months ago in the same area the molar 37 was extracted, achieving a complete satisfactory healing, when
only 2 doses of zoledronic acid had been administered. Actinomyces bacterial aggregates were also identified in the microscopic
analysis. The management of this osteonecrotic lesion included antibiotic treatment and chlorhexidine topical gel administration.
The evolution was monitored every two weeks until patient’s death. The authors provide a discussion of the etiology, pathogenesis,
diagnosis, and management. This case report may shed light on the controversies about concomitant factors and mechanisms
inducing ONJ.
1. Introduction
Osteonecrosis of the jaw (ONJ) is a site specific osseous
pathology, characterized by exposed bone in the mouth that
does not heal with 6 to 8 weeks of therapy. It is very likely that
ONJ is a clinical entity with many possible aetiologies and
its pathogenesis is not well understood [1]. The risk factors
for ONJ include bisphosphonates treatments, head and neck
radiotherapy, periodontal disease, dental procedures involv-
ing bone surgery, edentulous regions, and trauma for poorly
fitting dentures [2–6].
Additional risk factors in cancer patients include the
underlying malignancy, chemotherapy, corticosteroids, and
systemic or regional infection [7]. ONJ has been reported in
patients with a variety of tumour types, including multiple
myeloma. Frequently, these patients are receiving long-term
chemotherapy and many short-term intermittent corticos-
teroid therapies with concomitant bisphosphonate therapy
for cancer and symptom management [1]. Cancer patients
treated with intravenous bisphosphonates account for the
majority of bisphosphonate-related ONJ cases, although
individuals taking oral formulations, most often for osteo-
porosis, may also be affected [8].
These lesions typically become symptomatic in case of
secondary infections, trauma to adjacent soft tissues, or other
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Figure 1: (a) Clinical image. Chronic suppurated apical periodontitis of tooth 37. Notice the fistula in the buccal area of this molar. (b)
Radiological image. Notice the periapical radiolucent lesion in tooth 37.
more rare complications such as pathologic bone fracture
[1, 8].
The prevalence of ONJ is estimated to be 2–4% among
cancer patients and substantially lower (0.1–0.5%) in patients
taking oral bisphosphonates only [9–13]. These lesions are
more frequent on the mandible than the maxilla [1].
Management of ONJ has centred on efforts to eliminate
or reduce severity of symptoms, to slow or prevent the
progression of disease, and to eradicate diseased bone [8].
The objective of this paper is to report an unusual clinical
case of ONJ in a patient with multiple myeloma-related bone
disease.
2. Case Report
A 64-year-old Caucasian male was attended at Clinicians
Associates in Terrassa (Barcelona); the chief complaint was a
fistula on buccal area of tooth 37. At that time the patient was
diagnosedwithmultiplemyeloma stage III asymptomatic and
only 2 doses of zoledronic acid (4mg), once per month, have
been administrated via IV. After a thorough clinicoradiologi-
cal examination, a chronic suppurated apical periodontitis of
tooth 37 was confirmed (Figures 1(a) and 1(b)). Considering
that the analytical parameters were rather good and in order
to avoid any active infectious lesion before proceeding to
a bone marrow autotransplantation the extraction of this
secondmolarwas indicated. A couple of days before perform-
ing the conventional tooth extraction, antibiotic prophylaxis
with Amoxicillin 500mg/8 h and Metronidazole 500mg/8 h
was prescribed for 7 more days. The healing process had a
complete satisfactory evolution and one week later sutures
were removed. Two months later, bisphosphonate treatment
was reintroduced with calcium supplementation and six
months after the tooth extraction the clinicoradiological
control of this localization was normal (Figure 2).
One and a half year after that tooth extraction the patient
came for a routine control visit and he complained of slight
pain in the left posterior alveolar ridge, in the lingual area.
The patient mentioned that the discomfort started after a
traumatic injury duringmastication. Although radiologically
there was not any relevant findings, clinically only one
incipient point of inflamed mucosa was observed, which
seemed like a simple foreign body reaction. Chlorhexidine
topical gel was indicated and this lesion was monitored every
two or three weeks also by the oral and maxillofacial surgeon
in theMu´tua Terrassa Hospital.The lesion size increased and
an osteonecrosis of the jaw was the presumptive diagnosis.
According to the clinical features and the presence of a
sinus tract (Figures 3(a)–3(d)), antibiotic treatment was
initiated, Amoxicillin 500mg/8 h. In that moment the patient
had completed his proposed bisphosphonate therapy after
receiving the 6th dose of zoledronic acid (4mg) via IV. A
new panoramic radiography and a mandible computerized
tomography (CT) were performed. The radiological report
was not conclusive for osteonecrosis images, and only a lin-
gual thin fissure line was observed in the affected area among
a high bone density image (Figure 4). However, after 2-month
follow-up the biopsy was indicated and its histopathological
analysis confirmed the final diagnosis: osteonecrosis with
Actinomyces infection (Figures 5(a) and 5(b)).
Despite a transitory clinical improvement of the lesion,
its size was growing. The bone exposed area was greater con-
curring with the systemic corticosteroids administration in
order to treat an acute exacerbation of the multiple myeloma.
In a few days the patient general condition became worse
over time and his toxic syndrome evolution was aggravated.
About three weeks after the jaw lesion biopsy the patient was
admitted to the hospital emergencies with severe hemogram
alterations (leukocytes 1.66 × 109/L, erythrocytes 3.1 × 1012/L,
haemoglobin 9 gr/dL, and platelets 54 × 109/L). Finally, a
pneumonia due to Pseudomonas aeruginosa as an eventual
complication of his pancytopenia and a massive haemoptysis
episode precipitated his death.
3. Discussion
Usually the ONJ is a well-established bone disorder in
patients treated with bisphosphonates that develops exposed
necrotic bone in the oral cavity [14–16]. First report of a series
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Figure 2: (a) Panoramic radiograph. Notice the correct healing of the socket after 6 months of the molar 37 extraction. (b) Periapical
radiograph. Observe the satisfactory bone density in the socket after 6 months of extraction.
(a) (b)
(c) (d)
Figure 3: Clinical image. Progression of the lesion. (a) Notice the incipient mucositis and light tumefaction on the affected area. (b) Six weeks
later, notice the bone exposure and how the lesion is expanding in mesial direction. ((c) and (d)) Eight weeks later, notice the increase of bone
exposure and a characteristic sinus tract with its active exudation.
of ONJ cases associated with bisphosphonates was published
by Marx in 2003 [14].
There are two major theories regarding the pathophysi-
ology of bisphosphonate-related ONJ. The osteoclast-based,
“inside-out” theory, in which the inhibition of osteoclastic
activity and marked suppression of bone turnover, together
with spread of physiologic microdamage and possibly local
infection, leads to bone death within the jaw, with subsequent
exposure. The “outside-in” theory suggesting a break in the
oral mucosa leads to ingress of bacteria and local infection
which, coupled with poor bone remodelling, conduce to
bone death. Bisphosphonate-related ONJ may result from
combination of these two mechanisms and hypovascularity
also plays an important role [17, 18]. In our case the initial
minor traumatic injury might be the starting point of an
“outside-in” process.
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Figure 4: (a) Panoramic radiograph. Notice in the affected area a high bone density image. (b) CT image. Notice a lingual thin fissure line in
the affected area.
(a) (b)
Figure 5: Microscopic appearance. (a) Necrotic bone fragment with acute inflammatory reaction with polymorphonuclear. H&E. Original
magnification 20x. (b) Notice also the large bacterial aggregate consistent with Actinomyces. H&E. Original magnification 20x.
The risk of developing bisphosphonate-related osteone-
crosis of the jaw associated with oral bisphosphonates,
although exceedingly small, appears to increase when the
duration of therapy exceeds 3 years. The time of exposure is
a crucial factor for the development of ONJ [19]. It has been
suggested that development of bisphosphonate-related ONJ
requires a long period of exposure [16]. Bamias et al. observed
that no patient who received fewer than 13 intravenous
treatments with bisphosphonates developed osteonecrosis
[20]. The authors observed that patients who developed ONJ
received amedian number of 35 infusions and the cumulative
hazard increased above 1% after 12 months of treatment
with bisphosphonates up to 11% at 4 years [20]. Similar
observations have been reported by Durie et al. [21, 22]. In
our reported clinical case, it is important to notice that
when the tooth extraction was performed, only 2 doses
of bisphosphonates had been administrated so it is rather
unlikely a primary cause-effect with this drug. In addition the
alveolar socket after extraction healed successfully. Although
18 months later a new process started by a minor traumatic
injury to this area, when the patient had just received 6 infu-
sions of bisphosphonates, the majority of bisphosphonates-
related ONJ cases described in the literature highlight that
the lesion is due to an unsatisfactory alveolar socket healing
process after tooth extraction.
The clinical diagnosis of ONJ is usually made on the
basis of visual inspection and/or radiographic examination.
Panoramic and tomographic imaging may be performed
Table 1: International Staging System (ISS) for multiple myeloma.
Stage Criteria
I Serum 𝛽2 microglobulin < 3.5mg/L and serum albumin
≥ 3.5 g/dL
II
Serum 𝛽2 microglobulin < 3.5mg/L but serum albumin
< 3.5 g/dL or serum 𝛽2 microglobulin 3.5 to < 5.5mg/L
irrespective of the serum albumin level
III Serum 𝛽2 microglobulin ≥ 5.5mg/L
to rule out other entities, like cysts, impacted teeth, or
metastatic disease. The radiographic signs suggestive of ONJ
involve osteolysis consistent with bone loss, providing a
radiographic appearance similar to that observed in bone
metastasis. Initially,minimal detectable radiographic changes
are observed [1]. Contrarily, in our case report a high
bone density was observed in the extraction socket. Such
radiological feature could allow us to consider different but
concomitant aetiological factors in this ONJ process.
ONJ may remain asymptomatic for many weeks or
months and is usually identified by its unique clinical
presentation of exposed bone in the oral cavity. Signs and
symptoms of ONJ include localized discomfort, pain, soft-
tissue swelling and inflammation, loosening of previously
stable teeth, drainage, and exposed bone. These symptoms
most commonly occur at the site of previous tooth extraction
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Table 2: ONM staging and treatment strategies—American Association of Oral and Maxillofacial Surgeons 2009.
ONJ stage Description Treatment strategies
At risk category No apparent necrotic bone in patients who have been treated witheither oral or IV bisphosphonates
No treatment indicated
Patient education
Stage 0 No clinical evidence of necrotic bone, but nonspecific clinicalfindings and symptoms
Systemic management, including use of pain
medication and antibiotics
Stage 1 Exposed and necrotic bone in asymptomatic patients withoutevidence of infection
Antibacterial mouth rinse
Clinical follow-up on quarterly basis
Patient education and review of indications for
continued bisphosphonate therapy
Stage 2
Exposed and necrotic bone associated with infection as evidenced
by pain and erythema in region of exposed bone with or without
purulent drainage
Symptomatic treatment with oral antibiotics
Oral antibacterial mouth rinse
Pain control
Superficial debridement to relieve soft tissue
irritation
Stage 3
Exposed and necrotic bone in patients with pain, infection, and
one or more of the following: A—exposed and necrotic bone
extending beyond the region of alveolar bone, (i.e., inferior border
and ramus in the mandible or maxillary sinus and zygoma in the
maxilla) resulting in pathologic fracture, B—extraoral fistula and
oral antral/oral nasal communication, and C—osteolysis extending
to the inferior border of the mandible or the sinus floor
Antibacterial mouth rinse
Antibiotic therapy and pain control
Surgical debridement/resection for longer term
palliation of infection and pain.
or other dental surgical interventions but may occur sponta-
neously. Other atypical complaints are the feeling of “heavy
jaw,” “numbness,” and dysesthesia [1, 23, 24].
MM is characterized by osteolytic bone disease. The
patients affected by this incurable plasma-cell malignancy
present some additional risk factors, including the underlying
malignancy, chemotherapy, corticosteroids, and systemic or
regional infection [7]. Pancytopenia also increases the risk for
infection and development of osteomyelitis. Vascular insuffi-
ciency due to thrombosis has been associatedmechanistically
with the development of the ONJ [25]. This event is a con-
sequence of diminished arterial flow, increased intraosseous
venous pressure, and osseous hypoxia [26]. Coagulopathies,
typically manifested as thrombophilia or hypofibrinolysis,
have been implicated as contributory factors [27] as has
impaired blood flow secondary to edema or osteomyelitis
[28–30]. So in our case the concomitant MM might have
played an important role in the evolution of this ONJ. On the
other hand, themassive hemoptysis episode before his demise
would prove his severe coagulopathy.
Staging system of MM quantifies the extent of the disease
in the body. The most commonly used system since 1975
has been the Durie-Salmon (DS) staging system [31–34]. In
2005 a new international method was utilized for myeloma
prognosis based on the clinical and laboratory data. The
International Staging System (ISS) utilizes a combination of
serum 𝛽
2
microglobulin and serum albumin to provide a
simple, powerful, and reproducible three-stage classification
(Table 1).
According to Ruggiero et al., tissue biopsy should be
performed if metastatic disease is suspected. It has suggested
a microbial culture (aerobic and anaerobic), to identify
pathogens with the potential to cause secondary infections.
It is important to note that Actinomyces organisms are often
present [1].
Bisphosphonate-related ONJ was originally believed to
be a direct, noninfectious complication of bisphosphonate
therapy. However, recent histological and microbiological
data strongly support that Actinomyces play a critical role in
the pathogenesis of this disorder [35–40]. Actinomyces spp.
do not cause disease as long as they stay on the surface
of the mucosa. However, if the integrity of the mucosal
barrier is endangered and the bacteria gain access to the
oral tissues or jawbones, they may initiate a prolonged
chronic inflammatory process, creating a tumor-like mass,
tissue destruction, osteolysis, and multiple sinus tracts [41–
43]. During tissue invasion, Actinomyces form clumps called
sulphur granules [44].TheseActinomyces bacterial aggregates
were also identified in the microscopic analysis of our
patient’s biopsy (Figure 5).
The bisphosphonates were hypothesized to impede the
repair process, resulting in avascular osteonecrosis [45–47].
However, other observations put this hypothesis into ques-
tion and suggested that bisphosphonate use facilitates actino-
mycotic infection, resulting in osteonecrosis. Osteonecrosis
solely due to bisphosphonates has not been described in ani-
mals or humans with normal bone [44] and the concomitant
occurrence of Actinomyces infection with bisphosphonate-
related ONJ has been seen in an increasing number of cases
[35–40].
Management of ONJ has centred on efforts to elimi-
nate or reduce severity of symptoms, to slow or prevent
the progression of disease, and to eradicate diseased bone.
Specific management regimens have included chlorhexi-
dine rinses, antibiotic therapy, nonsurgical sequestrectomy
(simple removal of mobile bone fragments), and surgical
debridement and/or resection of necrotic bone [8].
American Academy of Oral and Maxillofacial Surgeons
(AAOMS) adopted stage system guidelines designed tomini-
mize symptoms and/or achieve resolution of lesions (Table 2).
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Table 3: Anti-infective pharmacologic treatments∗.
Treatment Dose and schedule
Antibacterials
Penicillin VK 500mg every 6 to 8 hours for 7 to 10 days and then every 12 hours for maintenance
Amoxicillin 500mg every 8 hours for 7 to 10 days and then every 12 hours for maintenance
Patients with penicillin allergy
Clindamycin 150 to 300mg every 6 hours
Vibramycin 100mg every 24 hours
Erythromycin ethylsuccinate 400mg every 8 hours
Azithromycin 500mg PO × 1 on day 1; 250mg oral every 6 hours on days 2 to 5
Antifungals† (when required)
Nystatin oral suspension 5 to 15mL every 6 hours or 100.000 IU/mL
Clotrimazole 10mg every 8 hours and every 5 hours on days 7 to 10
Fluconazole 200mg initially and then 100mg every 24 hours
Antivirals‡
Acyclovir 400mg every 12 hours
Valacyclovir hydrochloride 500mg to 2 g every 12 hours
†Other potential systemic antifungals include itraconazole or ketoconazole.
‡Role of antivirals in the treatment of osteonecrosis of the jaw has not yet been established.
∗Novartis (Basel, Switzerland), data on file.
Regardless of stage, chlorhexidine rinses were prescribed for
the majority of patients and mobile fragments of bone were
managed with nonsurgical sequestrectomy, typically with-
out the need for local anaesthesia. Asymptomatic patients
were typically managed with observation generally including
chlorhexidine. Symptomatic patients were generally treated
with antibiotics for management of pain or the presence
of sinus tracts until these resolved. Surgical debridement,
resection, and/or reconstruction were reserved for severe
cases and/or disease refractory at previous measures. Some
authors recommend staging the patients at the initial visit and
at each subsequent visit, in order to evaluate the course and
management outcomes [8].
Van den Wyngaert et al. observed that a combina-
tion of antimicrobial rinses, antibiotic therapy, nonsurgical
sequestrectomy, and local debridement is an appropriate and
effective approach for management of ONJ [48].
The goal of the intermittent or continuous antibiotic
therapy is to prevent secondary soft-tissue infection, pain,
and osteomyelitis. Microbial cultures should be collected
and analyzed to determine the appropriate antimicrobial
intervention. In some refractory cases, patients might require
combination antibiotic therapy, long-term antibiotic mainte-
nance, or course of IV antibiotic therapy [8]. Several antimi-
crobial pharmacologic therapies have been recommended
(Table 3).
4. Conclusion
This clinical case shows a singular presentation of an ONJ
in a patient with multiple myeloma-bone disease and other
concomitant factors. However, the traumatic mechanism
“outside-in” was the most probable origin of the lesion, as the
tooth extraction was performed 18 months ago with a satis-
factory healing. Moreover, the few doses of bisphosphonates
administrated might also support the infectious aetiology,
caused by Actinomyces, as a starting point.
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